Design Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows how the company's business is performing and whether it's spending money wisely.
Directors make important decisions about company strategy, so who they are matters to shareholders.
Independent auditors check company financial reports to make sure they're accurate and honest.
Progress in drug trials affects whether a biotech company's treatments will reach patients and generate sales.
Shows how the company's business is performing and whether it's spending money wisely.
Updated presentations help investors understand company strategy and financial direction.
New board members bring expertise and influence company decisions about future direction.
Stocky reads Design Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Design Therapeutics, Inc.'s most recent tracked filing was a 10-Q on 3 Aug 2026: Second quarter 2026 financial results reported.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.